Back to results
US 2004/0002080 A1Published application
Primers for use in detecting beta-lactamases
AssigneeCreighton University
InventorNancy D. Hanson
Life of this patent
Estimating the term…
Abstract
Oliognucleotide primers are provided that are specific for nucleic acid characteristic of certain beta-lactamases. The primers can be employed in methods to identify nucleic acid characteristic of family-specific beta-lactamase enzymes in samples, and particularly, in clinical isolates of Gram-negative bacteria.
Claims35
A primer selected from the group consisting of:
- 5′-GGAGCAGCAACGATGTTACG-3′ (SEQ ID NO:1);
- 5′-CGACTTGATTGAAGGGTTGG-3′ (SEQ ID NO:2);
- and full-length complements thereof.
A primer selected from the group consisting of:
- 5′-GCATTACTTCAGCTATGGGC-3′ (SEQ ID NO:3);
- 5′-GGCATTGGGATAGTTGCGGTTG-3′ (SEQ ID NO:4);
- and full-length complements thereof.
A primer selected from the group consisting of:
- 5′-CACCACGAGAATAACC-3′ (SEQ ID NO:5);
- 5′-GCCTTGAACTCGACCG-3′ (SEQ ID NO:6);
- and full-length complements thereof.
A primer selected from the group consisting of:
- 5′-CAATGTGTGAGAAGCAGTC-3′ (SEQ ID NO:7);
- 5′-CGCATGGGATTTTCCTTGCTG-3′ (SEQ ID NO:8);
- 5′-CGTTATGCTGCGCTCTGCTG-3′ (SEQ ID NO:9);
- 5′-CTGCGGAACCGTAATCCAGG-3′ (SEQ ID NO:10);
- 5′-CGTTATGCTGCGCTCTGC-3′ (SEQ ID NO:11);
- 5′-GGCGATATCGGCTTTACC-3′ (SEQ ID NO:12);
- and full-length complements thereof.
4 more elements
A primer selected from the group consisting of:
- 5′-CCGTTACTCACACACGGAAGG-3′ (SEQ ID NO:13);
- 5′-CGTATCCGCAGGGGCCTGTTC-3′ (SEQ ID NO:14);
- 5′-GCGTCTGTATGCAAACAGCAG-3′ (SEQ ID NO:15);
- 5′-CAATGCGACCTCGTTGGTCACG-3′ (SEQ ID NO:16);
- and full-length complements thereof.
2 more elements
A primer selected from the group consisting of:
- 5′-CCGATTAAAAGGTCAC-3′ (SEQ ID NO:17);
- 5′-GTGACTCAACATATCG-3′ (SEQ ID NO:18);
- 5′-CGTTAGCGTACTCAATGTGG-3′ (SEQ ID NO:19);
- 5′-GATCCTGAGTAATCTCACCC-3′ (SEQ ID NO:20);
- and full-length complements thereof.
2 more elements
A primer selected from the group consisting of:
- 5′-CCTGCAACCTAAGAGAGCTTCT-3′ (SEQ ID NO:21);
- 5′-CGCGGTGGATGATGTGGTAA-3′ (SEQ ID NO:22);
- and full-length complements thereof.
A primer selected from the group consisting of:
- 5′-CCGGATGAGGTCAAGGATAACGC-3′ (SEQ ID NO:23);
- 5′-CCCCAGGCGTAATGCGCCTCTTCC-3′ (SEQ ID NO:24);
- and full-length complements thereof.
A primer selected from the group consisting of:
- 5′-GCTACACCTAGCTCCACCTTC-3′ (SEQ ID NO:25);
- 5′-GACAGTGGTTGGTAATCCATGC-3′ (SEQ ID NO:26);
- 5′-GTATCGCCGTCTAGTTCTGC-3′ (SEQ ID NO:27);
- 5′-GGTCGTGTTTCCCTTTAGCC-3′ (SEQ ID NO:28);
- 5′-GGTAATCTGGCACGCATGGT-3′ (SEQ ID NO:29);
- 5′-CACACTGAGCATATGCTGAC-3′ (SEQ ID NO:30);
- 5′-GGCCAATACAAAGGGCATCG-3′ (SEQ ID NO:31);
- 5′-CTACCCAATCGCTTGGTACG-3′ (SEQ ID NO:32);
- and full-length complements thereof.
6 more elements
A method for identifying a beta-lactamase nucleic acid in a clinical sample, the method comprising:
- providing a clinical sample;
- contacting the clinical sample with a pair of oligonucleotide primers specific for nucleic acid characteristic of the OXA-30 beta-lactamase enzyme, wherein one primer of the pair is complementary to at least a portion of the beta-lactamase nucleic acid in the sense strand and the other primer of each pair is complementary to at least a portion of the beta-lactamase nucleic acid in the antisense strand;
- annealing the primers to the beta-lactamase nucleic acid;
- simultaneously extending the annealed primers from a 3′ terminus of each primer to synthesize an extension product that is complementary to the nucleic acid strands annealed to each primer wherein each extension product after separation from the beta-lactamase nucleic acid serves as a template for the synthesis of an extension product for the other primer of each pair;
- separating the amplified products;
- and
- analyzing the separated amplified products for a size characteristic of the beta-lactamase nucleic acid.
4 more elements
A method for identifying a beta-lactamase nucleic acid in a clinical sample, the method comprising:
- providing a clinical sample;
- contacting the clinical sample with a pair of oligonucleotide primers having sequences 5′-GCATTACTTCAGCTATGGGC-3′ (SEQ ID NO:3), or a full-length complement thereof, and
- 5′-GGCATTGGGATAGTTGCGGTTG-3′ (SEQ ID NO:4), or a full-length complement thereof, wherein one primer of the pair is complementary to at least a portion of the beta-lactamase nucleic acid in the sense strand and the other primer of each pair is complementary to at least a portion of the beta-lactamase nucleic acid in the antisense strand;
- annealing the primers to the beta-lactamase nucleic acid;
- simultaneously extending the annealed primers from a 3′ terminus of each primer to synthesize an extension product that is complementary to the nucleic acid strands annealed to each primer wherein each extension product after separation from the beta-lactamase nucleic acid serves as a template for the synthesis of an extension product for the other primer of each pair;
- separating the amplified products;
- and
- analyzing the separated amplified products for a size characteristic of the beta-lactamase.
5 more elements
A method for identifying a beta-lactamase nucleic acid in a clinical sample, the method comprising:
- providing a clinical sample;
- contacting the clinical sample with a pair of oligonucleotide primers having sequences 5′-CACCACGAGAATAACC-3′ (SEQ ID NO:5), or a full-length complement thereof, and 5′-GCCTTGAACTCGACCG-3′ (SEQ ID NO:6), or a full-length complement thereof, wherein one primer of the pair is complementary to at least a portion of the beta-lactamase nucleic acid in the sense strand and the other primer of each pair is complementary to at least a portion of the beta-lactamase nucleic acid in the antisense strand;
- annealing the primers to the beta-lactamase nucleic acid;
- simultaneously extending the annealed primers from a 3′ terminus of each primer to synthesize an extension product that is complementary to the nucleic acid strands annealed to each primer wherein each extension product after separation from the beta-lactamase nucleic acid serves as a template for the synthesis of an extension product for the other primer of each pair;
- separating the amplified products;
- and
- analyzing the separated amplified products for a size characteristic of the beta-lactamase.
4 more elements
A method for identifying a beta-lactamase nucleic acid in a clinical sample, the method comprising:
- providing a clinical sample;
- contacting the clinical sample with a pair of oligonucleotide primers specific for nucleic acid characteristic of the FOX-5 beta-lactamase enzyme, wherein one primer of the pair is complementary to at least a portion of the beta-lactamase nucleic acid in the sense strand and the other primer of each pair is complementary to at least a portion of the beta-lactamase nucleic acid in the antisense strand;
- annealing the primers to the beta-lactamase nucleic acid;
- simultaneously extending the annealed primers from a 3′ terminus of each primer to synthesize an extension product that is complementary to the nucleic acid strands annealed to each primer wherein each extension product after separation from the beta-lactamase nucleic acid serves as a template for the synthesis of an extension product for the other primer of each pair;
- separating the amplified products;
- and
- analyzing the separated amplified products for a size characteristic of the beta-lactamase nucleic acid.
4 more elements
A method for identifying a beta-lactamase nucleic acid in a clinical sample, the method comprising:
- providing a clinical sample;
- contacting the clinical sample with a pair of oligonucleotide primers selected from the group consisting of 5′-CAATGTGTGAGAAGCAGTC-3′ (SEQ ID NO:7), 5′-CGCATGGGATTTTCCTTGCTG-3′ (SEQ ID NO:8), 5′-CGTTATGCTGCGCTCTGCTG-3′ (SEQ ID NO:9), 5′-CTGCGGAACCGTAATCCAGG-3′ (SEQ ID NO:10), 5′-CGTTATGCTGCGCTCTGC-3′ (SEQ ID NO:11), 5′- GGCGATATCGGCTTTACC-3′ (SEQ ID NO:12), and full-length complements thereof, wherein one primer of the pair is complementary to at least a portion of the beta-lactamase nucleic acid in the sense strand and the other primer of each pair is complementary to at least a portion of the beta-lactamase nucleic acid in the antisense strand;
- annealing the primers to the beta-lactamase nucleic acid;
- simultaneously extending the annealed primers from a 3′ terminus of each primer to synthesize an extension product that is complementary to the nucleic acid strands annealed to each primer wherein each extension product after separation from the beta-lactamase nucleic acid serves as a template for the synthesis of an extension product for the other primer of each pair;
- separating the amplified products;
- and
- analyzing the separated amplified products for a size characteristic of the beta-lactamase.
4 more elements
A method for identifying a beta-lactamase nucleic acid in a clinical sample, the method comprising:
- providing a clinical sample;
- contacting the clinical sample with a pair of oligonucleotide primers specific for nucleic acid characteristic of the plasmid-mediated AmpC beta-lactamase enzymes derived from Morganella morganii, wherein one primer of the pair is complementary to at least a portion of the beta-lactamase nucleic acid in the sense strand and the other primer of each pair is complementary to at least a portion of the beta-lactamase nucleic acid in the antisense strand;
- annealing the primers to the beta-lactamase nucleic acid;
- simultaneously extending the annealed primers from a 3′ terminus of each primer to synthesize an extension product that is complementary to the nucleic acid strands annealed to each primer wherein each extension product after separation from the beta-lactamase nucleic acid serves as a template for the synthesis of an extension product for the other primer of each pair;
- separating the amplified products;
- and
- analyzing the separated amplified products for a size characteristic of the beta-lactamase.
4 more elements
A method for identifying a beta-lactamase nucleic acid in a clinical sample, the method comprising:
- providing a clinical sample;
- contacting the clinical sample with a pair of oligonucleotide primers specific for nucleic acid characteristic of the plasmid-mediated AmpC beta-lactamase enzymes derived from Hafnia alvei, wherein one primer of the pair is complementary to at least a portion of the beta-lactamase nucleic acid in the sense strand and the other primer of each pair is complementary to at least a portion of the beta-lactamase nucleic acid in the antisense strand;
- annealing the primers to the beta-lactamase nucleic acid;
- simultaneously extending the annealed primers from a 3′ terminus of each primer to synthesize an extension product that is complementary to the nucleic acid strands annealed to each primer wherein each extension product after separation from the beta-lactamase nucleic acid serves as a template for the synthesis of an extension product for the other primer of each pair;
- separating the amplified products;
- and
- analyzing the separated amplified products for a size characteristic of the beta-lactamase.
4 more elements
A method for identifying a beta-lactamase nucleic acid in a clinical sample, the method comprising:
- providing a clinical sample;
- contacting the clinical sample with a pair of oligonucleotide primers having sequences 5′-CCTGCAACCTAAGAGAGCTTCT-3′ (SEQ ID NO:21), or a full-length complement thereof, and 5′-GCGCCTGGATGATGTGGTAA-3′ (SEQ ID NO:22), or a full-length complements thereof, wherein one primer of the pair is complementary to at least a portion of the beta-lactamase nucleic acid in the sense strand and the other primer of each pair is complementary to at least a portion of the beta-lactamase nucleic acid in the antisense strand;
- annealing the primers to the beta-lactamase nucleic acid;
- simultaneously extending the annealed primers from a 3′ terminus of each primer to synthesize an extension product that is complementary to the nucleic acid strands annealed to each primer wherein each extension product after separation from the beta-lactamase nucleic acid serves as a template for the synthesis of an extension product for the other primer of each pair;
- separating the amplified products;
- and
- analyzing the separated amplified products for a size characteristic of the beta-lactamase.
4 more elements
A method for identifying a beta-lactamase nucleic acid in a clinical sample, the method comprising:
- providing a clinical sample;
- contacting the clinical sample with a pair of oligonucleotide primers specific for nucleic acid characteristic of the plasmid-mediated AmpC beta-lactamase enzymes designated as MIR-1 and ACT-1, wherein one primer of the pair is complementary to at least a portion of the beta-lactamase nucleic acid in the sense strand and the other primer of each pair is complementary to at least a portion of the beta-lactamase nucleic acid in the antisense strand;
- annealing the primers to the beta-lactamase nucleic acid;
- simultaneously extending the annealed primers from a 3′ terminus of each primer to synthesize an extension product that is complementary to the nucleic acid strands annealed to each primer wherein each extension product after separation from the beta-lactamase nucleic acid serves as a template for the synthesis of an extension product for the other primer of each pair;
- separating the amplified products;
- and
- analyzing the separated amplified products for a size characteristic of the beta-lactamase.
4 more elements
A method for identifying a beta-lactamase nucleic acid in a clinical sample, the method comprising:
- providing a clinical sample;
- contacting the clinical sample with a pair of oligonucleotide primers specific for nucleic acid characteristic of the plasmid-mediated AmpC beta-lactamase enzymes derived from Enterobacter cloacae, wherein one primer of the pair is complementary to at least a portion of the beta-lactamase nucleic acid in the sense strand and the other primer of each pair is complementary to at least a portion of the beta-lactamase nucleic acid in the antisense strand;
- annealing the primers to the beta-lactamase nucleic acid;
- simultaneously extending the annealed primers from a 3′ terminus of each primer to synthesize an extension product that is complementary to the nucleic acid strands annealed to each primer wherein each extension product after separation from the beta-lactamase nucleic acid serves as a template for the synthesis of an extension product for the other primer of each pair;
- separating the amplified products;
- and
- analyzing the separated amplified products for a size characteristic of the beta-lactamase;
- wherein the primers are selected from the group consisting of:
- 5′-CCGGATGAGGTCAAGGATAACGC-3′ (SEQ ID NO:23);
- 5′-CCCCAGGCGTAATGCGCCTCTTCC-3′ (SEQ ID NO:24);
- and full-length complements thereof.
8 more elements
A method for identifying a beta-lactamase nucleic acid in a clinical sample, the method comprising:
- providing a clinical sample;
- contacting the clinical sample with a pair of oligonucleotide primers specific for nucleic acid characteristic of an AmpC beta-lactamase enzyme, wherein one primer of the pair is complementary to at least a portion of the beta-lactamase nucleic acid in the sense strand and the other primer of each pair is complementary to at least a portion of the beta-lactamase nucleic acid in the antisense strand;
- annealing the primers to the beta-lactamase nucleic acid;
- simultaneously extending the annealed primers from a 3′ terminus of each primer to synthesize an extension product that is complementary to the nucleic acid strands annealed to each primer wherein each extension product after separation from the beta-lactamase nucleic acid serves as a template for the synthesis of an extension product for the other primer of each pair;
- separating the amplified products;
- and
- analyzing the separated amplified products for a size characteristic of the beta-lactamase;
- wherein the primers are selected from the group consisting of:
- 5′-GCATTACTTCAGCTATGGGC-3′ (SEQ ID NO:3);
- 5′-GGCATTGGGATAGTTGCGGTTG-3′ (SEQ ID NO:4);
- 5′-CACCACGAGAATAACC-3′ (SEQ ID NO:5);
- 5′-GCCTTGAACTCGACCG-3′ (SEQ ID NO:6);
- 5′-CAATGTGTGAGAAGCAGTC-3′ (SEQ ID NO:7);
- 5′-CGCATGGGATTTTCCTTGCTG-3′ (SEQ ID NO:8);
- 5′-CGTTATGCTGCGCTCTGCTG-3′ (SEQ ID NO:9);
- 5′-CTGCGGAACCGTAATCCAGG-3′ (SEQ ID NO:10);
- 5′-CGTTATGCTGCGCTCTGC-3′ (SEQ ID NO:11);
- 5′-GGCGATATCGGCTTTACC-3′ (SEQ ID NO:12);
- 5′-CCGTTACTCACACACGGAAGG-3′ (SEQ ID NO:13);
- 5′-CGTATCCGCAGGGGCCTGTTC-3′ (SEQ ID NO:14);
- 5′-GCGTCTGTATGCAAACAGCAG-3′ (SEQ ID NO:15);
- 5′-CAATGCGACCTCGTTGGTCACG-3′ (SEQ ID NO:16);
- 5′-CCGATTAAAAGGTCAC-3′ (SEQ ID NO:17);
- 5′-GTGACTCAACATATCG-3′ (SEQ ID NO:18);
- 5′-CGTTAGCGTACTCAATGTGG-3′ (SEQ ID NO:19);
- 5′-GATCCTGAGTAATCTCACCC-3′ (SEQ ID NO:20);
- 5′-CCTGCAACCTAAGAGAGCTTCT-3′ (SEQ ID NO:21);
- 5′-GCGCCTGGATGATGTGGTAA-3′ (SEQ ID NO:22);
- 5′-CCGGATGAGGTCAAGGATAACGC-3′ (SEQ ID NO:23);
- 5′-CCCCAGGCGTAATGCGCCTCTTCC-3′ (SEQ ID NO:24);
- and full-length complements thereof.
28 more elements
A method for identifying a beta-lactamase nucleic acid in a clinical sample, the method comprising:
- providing a clinical sample;
- contacting the clinical sample with a pair of oligonucleotide primers specific for nucleic acid characteristic of a beta-lactamase enzyme, wherein one primer of the pair is complementary to at least a portion of the beta-lactamase nucleic acid in the sense strand and the other primer of each pair is complementary to at least a portion of the beta-lactamase nucleic acid in the antisense strand;
- annealing the primers to the beta-lactamase nucleic acid;
- simultaneously extending the annealed primers from a 3′ terminus of each primer to synthesize an extension product that is complementary to the nucleic acid strands annealed to each primer wherein each extension product after separation from the beta-lactamase nucleic acid serves as a template for the synthesis of an extension product for the other primer of each pair;
- separating the amplified products;
- and
- analyzing the separated amplified products for a size characteristic of the beta-lactamase;
- wherein the primers are selected from the group consisting of:
- 5′-GGAGCAGCAACGATGTTACG-3′ (SEQ ID NO:1);
- 5′-CGACTTGATTGAAGGGTTGG-3′ (SEQ ID NO:2);
- 5′-GCATTACTTCAGCTATGGGC-3′ (SEQ ID NO:3);
- 5′-GGCATTGGGATAGTTGCGGTTG-3′ (SEQ ID NO:4);
- 5′-CACCACGAGAATAACC-3′ (SEQ ID NO:5);
- 5′-GCCTTGAACTCGACCG-3′ (SEQ ID NO:6);
- 5′-CAATGTGTGAGAAGCAGTC-3′ (SEQ ID NO:7);
- 5′-CGCATGGGATTTTCCTTGCTG-3′ (SEQ ID NO:8);
- 5′-CGTTATGCTGCGCTCTGCTG-3′ (SEQ ID NO:9);
- 5′-CTGCGGAACCGTAATCCAGG-3′ (SEQ ID NO:10);
- 5′-CGTTATGCTGCGCTCTGC-3′ (SEQ ID NO:11);
- 5′-GGCGATATCGGCTTTACC-3′ (SEQ ID NO:12);
- 5′-CCGTTACTCACACACGGAAGG-3′ (SEQ ID NO:13);
- 5′-CGTATCCGCAGGGGCCTGTTC-3′ (SEQ ID NO:14);
- 5′-GCGTCTGTATGCAAACAGCAG-3′ (SEQ ID NO:15);
- 5′-CAATGCGACCTCGTTGGTCACG-3′ (SEQ ID NO:16);
- 5′-CCGATTAAAAGGTCAC-3′ (SEQ ID NO:17);
- 5′-GTGACTCAACATATCG-3′ (SEQ ID NO:18);
- 5′-CGTTAGCGTACTCAATGTGG-3′ (SEQ ID NO:19);
- 5′-GATCCTGAGTAATCTCACCC-3′ (SEQ ID NO:20);
- 5′-CCTGCAACCTAAGAGAGCTTCT-3′ (SEQ IDNO:21);
- 5′-GCGCCTGGATGATGTGGTAA-3′ (SEQ ID NO:22);
- 5′-CCGGATGAGGTCAAGGATAACGC-3′ (SEQ ID NO:23);
- 5′-CCCCAGGCGTAATGCGCCTCTTCC-3′ (SEQ ID NO:24);
- 5′-GCTACACCTAGCTCCACCTTC-3′ (SEQ ID NO:25);
- 5′-GACAGTGGTTGGTAATCCATGC-3′ (SEQ ID NO:26);
- 5′-GTATCGCCGTCTAGTTCTGC-3′ (SEQ ID NO:27);
- 5′-GGTCGTGTTTCCCTTTAGCC-3′ (SEQ ID NO:28);
- 5′-GGTAATCTGGCACGCATGGT-3′ (SEQ ID NO:29);
- 5′-CACACTGAGCATATGCTGAC-3′ (SEQ ID NO:30);
- 5′-GGCCAATACAAAGGGCATCG-3′ (SEQ ID NO:31);
- 5′-CTACCCAATCGCTTGGTACG-3′ (SEQ ID NO:32);
- and full-length complements thereof.
38 more elements
A method for identifying a beta-lactamase nucleic acid in a clinical sample, the method comprising:
- providing a clinical sample;
- contacting the clinical sample with a pair of oligonucleotide primers specific for nucleic acid characteristic of carbapenem-hydrolyzing beta-lactamase enzymes, wherein one primer of the pair is complementary to at least a portion of the beta-lactamase nucleic acid in the sense strand and the other primer of each pair is complementary to at least a portion of the beta-lactamase nucleic acid in the antisense strand;
- annealing the primers to the beta-lactamase nucleic acid;
- simultaneously extending the annealed primers from a 3′ terminus of each primer to synthesize an extension product that is complementary to the nucleic acid strands annealed to each primer wherein each extension product after separation from the beta-lactamase nucleic acid serves as a template for the synthesis of an extension product for the other primer of each pair;
- separating the amplified products;
- and
- analyzing the separated amplified products for a size characteristic of the beta-lactamase.
4 more elements
A diagnostic kit for detecting an OXA-30 beta-lactamase nucleic acid, wherein the kit comprises:
- (a) at least one primer pair capable of hybridizing to a beta-lactamase nucleic acid;
- (b) at least one positive control and at least one negative control;
- and
- (c) a protocol for identification of the beta-lactamase nucleic acid, wherein the primers are selected from the group consisting of:
- 5′- GGAGCAGCAACGATGTTACG - 3′ (SEQ ID NO:1);
- 5′-CGACTTGATTGAAGGGTTGG -3′ (SEQ ID NO:2);
- and full-length complements thereof.
4 more elements
A diagnostic kit for detecting an AmpC family beta-lactamase, wherein the kit comprises:
- (a) at least one primer pair capable of hybridizing to a beta-lactamase nucleic acid;
- (b) at least one positive control and at least one negative control;
- and
- (c) a protocol for identification of the beta-lactamase nucleic acid, wherein at least one of the primers of the primer pair is selected from the group consisting of:
- 5′-GCATTACTTCAGCTATGGGC-3′ (SEQ ID NO:3);
- 5′-GGCATTGGGATAGTTGCGGTTG-3′ (SEQ ID NO:4);
- 5′-CACCACGAGAATAACC-3′ (SEQ ID NO:5);
- 5′-GCCTTGAACTCGACCG-3′ (SEQ ID NO:6);
- 5′-CAATGTGTGAGAAGCAGTC-3′ (SEQ ID NO:7);
- 5′-CGCATGGGATTTTCCTTGCTG-3′ (SEQ ID NO:8);
- 5′-CGTTATGCTGCGCTCTGCTG-3′ (SEQ ID NO:9);
- 5′-CTGCGGAACCGTAATCCAGG-3′ (SEQ ID NO:10);
- 5′-CGTTATGCTGCGCTCTGC-3′ (SEQ ID NO:11);
- 5′-GGCGATATCGGCTTTACC-3′ (SEQ ID NO:12);
- 5′-CCGTTACTCACACACGGAAGG-3′ (SEQ ID NO:13);
- 5′-CGTATCCGCAGGGGCCTGTTC-3′ (SEQ ID NO:14);
- 5′-GCGTCTGTATGCAAACAGCAG-3′ (SEQ ID NO:15);
- 5′-CAATGCGACCTCGTTGGTCACG-3′ (SEQ ID NO:16);
- 5′-CCGATTAAAAGGTCAC-3′ (SEQ ID NO:17);
- 5′-GTGACTCAACATATCG-3′ (SEQ ID NO:18);
- 5′-CGTTAGCGTACTCAATGTGG-3′ (SEQ ID NO:19);
- 5′-GATCCTGAGTAATCTCACCC-3′ (SEQ ID NO:20);
- 5′-CCTGCAACCTAAGAGAGCTTCT-3′ (SEQ ID NO:21);
- 5′-GCGCCTGGATGATGTGGTAA-3′ (SEQ ID NO:22);
- 5′-CCGGATGAGGTCAAGGATAACGC-3′ (SEQ ID NO:23);
- 5′-CCCCAGGCGTAATGCGCCTCTTCC-3′ (SEQ ID NO:24);
- and full-length complements thereof.
24 more elements
A diagnostic kit for detecting a carbapenem-hydrolyzing beta-lactamase, wherein the kit comprises:
- (a) at least one primer pair capable of hybridizing to a beta-lactamase nucleic acid;
- (b) at least one positive control and at least one negative control;
- and
- (c) a protocol for identification of the beta-lactamase nucleic acid.
1 more element
A diagnostic kit for detecting a beta-lactamase nucleic acid, wherein the kit comprises:
- (a) at least one primer pair capable of hybridizing to a beta-lactamase nucleic acid;
- (b) at least one positive control and at least one negative control;
- and
- (c) a protocol for identification of the beta-lactamase nucleic acid, wherein the primers are selected from the group consisting of:
- 5′-GGAGCAGCAACGATGTTACG-3′ (SEQ ID NO:1);
- 5′-CGACTTGATTGAAGGGTTGG-3′ (SEQ ID NO:2);
- 5′-GCATTACTTCAGCTATGGGC-3′ (SEQ ID NO:3);
- 5′-GGCATTGGGATAGTTGCGGTTG-3′ (SEQ ID NO:4);
- 5′-CACCACGAGAATAACC-3′ (SEQ ID NO:5);
- 5′-GCCTTGAACTCGACCG-3′ (SEQ ID NO:6);
- 5′-CAATGTGTGAGAAGCAGTC-3′ (SEQ ID NO:7);
- 5′-CGCATGGGATTTTCCTTGCTG-3′ (SEQ ID NO:8);
- 5′-CGTTATGCTGCGCTCTGCTG-3′ (SEQ ID NO:9);
- 5′-CTGCGGAACCGTAATCCAGG-3′ (SEQ ID NO:10);
- 5′-CGTTATGCTGCGCTCTGC-3′ (SEQ ID NO:11);
- 5′-GGCGATATCGGCTTTACC-3′ (SEQ ID NO:12);
- 5′-CCGTTACTCACACACGGAAGG-3′ (SEQ ID NO:13);
- 5′-CGTATCCGCAGGGGCCTGTTC-3′ (SEQ ID NO:14);
- 5′-GCGTCTGTATGCAAACAGCAG-3′ (SEQ ID NO:15);
- 5′-CAATGCGACCTCGTTGGTCACG-3′ (SEQ ID NO:16);
- 5′-CCGATTAAAAGGTCAC-3′ (SEQ ID NO:17);
- 5′-GTGACTCAACATATCG-3′ (SEQ ID NO:18);
- 5′-CGTTAGCGTACTCAATGTGG-3′ (SEQ ID NO:19);
- 5′-GATCCTGAGTAATCTCACCC-3′ (SEQ ID NO:20);
- 5′-CCTGCAACCTAAGAGAGCTTCT-3′ (SEQ IDNO:21);
- 5′-GCGCCTGGATGATGTGGTAA-3′ (SEQ ID NO:22);
- 5′-CCGGATGAGGTCAAGGATAACGC-3′ (SEQ ID NO:23);
- 5′-CCCCAGGCGTAATGCGCCTCTTCC-3′ (SEQ ID NO:24);
- 5′-GCTACACCTAGCTCCACCTTC-3′ (SEQ ID NO:25);
- 5′-GACAGTGGTTGGTAATCCATGC-3′ (SEQ ID NO:26);
- 5′-GTATCGCCGTCTAGTTCTGC-3′ (SEQ ID NO:27);
- 5′-GGTCGTGTTTCCCTTTAGCC-3′ (SEQ ID NO:28);
- 5′-GGTAATCTGGCACGCATGGT-3′ (SEQ ID NO:29);
- 5′-CACACTGAGCATATGCTGAC-3′ (SEQ ID NO:30);
- 5′-GGCCAATACAAAGGGCATCG-3′ (SEQ ID NO:31);
- 5′-CTACCCAATCGCTTGGTACG-3′ (SEQ ID NO:32);
- and full-length complements thereof.
34 more elements
Dependencies are inferred from the claim text.